rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2008-4-3-101-104rpcardio-1120Research ArticlePOINT OF VIEWТОЧКА ЗРЕНИЯROLE OF BETA-ADRENOBLOCKERS IN ARTERIAL HYPERTENSION TREATMENT. WHAT DO EVIDENCE BASED MEDICINE DATA SHOW?РОЛЬ БЕТА-АДРЕНОБЛОКАТОРОВ В ЛЕЧЕНИИ АРТЕРИАЛЬНОЙ ГИПЕРТОНИИ. О ЧЕМ СВИДЕТЕЛЬСТВУЮТ ДАННЫЕ ДОКАЗАТЕЛЬНОЙ МЕДИЦИНЫ?МарцевичС. Ю.MartsevichS. Y.

Кафедра доказательной медицины

Chair of evidence based medicine,

Государственный научно-исследовательский центр профилактической медицины Росмедтехнологий, Москва Московская медицинская академия им. И.М. СеченоваРоссияState Research Center of Preventive Medicine of Rosmedtechnology, Moscow Moscow Medical Academy named after I.M. SetchenovRussian Federation20083001201643101104Copyright © Martsevich S.Y., 20162016Марцевич С.Ю.Martsevich S.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/1120

The beta-blocker role in arterial hypertension treatment is surveyed from the positions of evidence based medicine and international clinical guidelines. Data of last randomized clinical trials and meta-analyses are discussed.

C позиций доказательной медицины и международных клинических рекомендаций рассматривается роль бета-адреноблокаторов в лече- нии артериальной гипертонии. Анализируются данные последних рандомизированных клинических исследований и мета-анализов.

артериальная гипертониябета-адреноблокаторыarterial hypertensionbeta-blockersReferencesMedical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J 1985;291:97-104.Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J 1985;291:97-104.IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens 1985;3:379-92.IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens 1985;3:379-92.Wilhelmsen L., Berglund G., Elmfeldt D. et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987;5:561-72.Wilhelmsen L., Berglund G., Elmfeldt D. et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987;5:561-72.Wikstrand J., Warnold I., Tuomilehto J. et al. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from MAPHY study. Hypertension 1991;17:570-88.Wikstrand J., Warnold I., Tuomilehto J. et al. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from MAPHY study. Hypertension 1991;17:570-88.MRC Working Party. Medical Research Council trial of treatment of hypertension in older patients: principal results. BMJ 1992;304:405-12.MRC Working Party. Medical Research Council trial of treatment of hypertension in older patients: principal results. BMJ 1992;304:405-12.Hansson L., Lindholm L., Dahlof B. et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-6.Hansson L., Lindholm L., Dahlof B. et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-6.Dahlof B., Devereux R., Kjeldsen S. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized study against atenolol. Lancet 2002;359:995-1003.Dahlof B., Devereux R., Kjeldsen S. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized study against atenolol. Lancet 2002;359:995-1003.Pepine C.J., Handberg E.M., Cooper-DeHoff R.M. et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International VerapamilTrandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290: 2805-16.Pepine C.J., Handberg E.M., Cooper-DeHoff R.M. et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International VerapamilTrandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290: 2805-16.Hansson L., Hedner T., Lund-Johansen P. et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:359-65.Hansson L., Hedner T., Lund-Johansen P. et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:359-65.Dahlof B., Sever P., Wedel H. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005;366(9489):895-906.Dahlof B., Sever P., Wedel H. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005;366(9489):895-906.Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35.Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35.Lindholm L., Carlberg B., Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-53.Lindholm L., Carlberg B., Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-53.Beevers D.G. The end of beta-blockers for uncomplicated hypertension? Lancet 2005;366:1510-2.Beevers D.G. The end of beta-blockers for uncomplicated hypertension? Lancet 2005;366:1510-2.Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008;336(7653):1121-3.Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008;336(7653):1121-3.Elliott W., Meyer P. Incident diabetes in clinical trial of antihypertensive drugs: a network meta-analysis. Lancet 2007;369:201-7.Elliott W., Meyer P. Incident diabetes in clinical trial of antihypertensive drugs: a network meta-analysis. Lancet 2007;369:201-7.UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: a UKPDS study. BMJ 1998;317:713-20.UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: a UKPDS study. BMJ 1998;317:713-20.Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87.Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87.Messerli F., Bell D., Fonseca V. et al. Body weight changes with betablocker use: results from GEMINI. Am J Med 2007;120:610-5.Messerli F., Bell D., Fonseca V. et al. Body weight changes with betablocker use: results from GEMINI. Am J Med 2007;120:610-5.

The authors declare that there are no conflicts of interest present.